David Reed, MD
Urology · Burien, WANPI 1912945791
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Verathon Inc. at 51.8% of the total. Reporting peaked in 2023 at $4,250 and has fallen 91.5% since, to $362 in 2025.
Across 144 payments — averaging $60.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verathon Inc.$5K
- Boston Scientific$1K
- Ferring Pharmaceuticals Inc.$425
- Astellas Pharma US Inc$392
- Johnson & Johnson$274
- Amgen$255
- plus $2K from 18 others
What the payments were for
- Consulting fees$4,50052%
- Travel & lodging$4705%
- Food & beverage$3,48440%
- Education$2373%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Verathon Inc. | 2 | $4,500 |
| Boston Scientific | 12 | $1,077 |
| Ferring Pharmaceuticals Inc. | 10 | $425 |
| Astellas Pharma US Inc | 18 | $392 |
| Johnson & Johnson | 13 | $274 |
| Amgen | 7 | $255 |
| Bayer | 11 | $241 |
| Dendreon Pharmaceuticals LLC | 12 | $240 |
| AbbVie | 10 | $213 |
| Janssen Scientific Affairs, LLC | 6 | $211 |
| Pfizer | 12 | $184 |
| Myovant Sciences Inc. | 6 | $160 |
| 180 Medical, Inc. | 3 | $97 |
| Coloplast | 4 | $62 |
| Rochester Medical Corporation | 3 | $58 |
| Convatec Inc. | 2 | $53 |
| Dentsply IH AB | 3 | $50 |
| AstraZeneca | 2 | $39 |
| Dentsply IH Inc. | 1 | $38 |
| Myriad Genetic Laboratories, Inc. | 2 | $37 |
| Urogen Pharma, Inc. | 1 | $25 |
| Urovant Sciences Inc | 2 | $25 |
| Laborie Medical Technologies Corp. | 1 | $16 |
| Teleflex LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NPD Clinical Study & Bronchoscope$4,250
- AMS$515
- FIRMAGON$340
- NPD Clinical Study$250
- ADVANCE$135
- GENERAL ERECTILE DYSFUNCTION$112
- ORGOVYX$110
How this compares
$8,690 in reported general payments places this provider in the 80th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Solifenacin Succinate | 77 | $1,969 |
| Tamsulosin Hcl | 100 | $745 |
| Silodosin | 16 | $684 |
| Finasteride | 16 | $125 |
| Ciprofloxacin Hcl | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Other urology in Burien
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Raymond LanceSpokane$211K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Kevin OstrowskiKirkland$64K
- Marco SalazarEdmonds$58K
- Anthony BuiVancouver$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.